A Liver-Derived Secretory Protein, Selenoprotein P, Causes Insulin Resistance  by Misu, Hirofumi et al.
Cell Metabolism
ArticleA Liver-Derived Secretory Protein,
Selenoprotein P, Causes Insulin Resistance
Hirofumi Misu,1,10 Toshinari Takamura,1,10,* Hiroaki Takayama,1 Hiroto Hayashi,1 Naoto Matsuzawa-Nagata,1
Seiichiro Kurita,1 Kazuhide Ishikura,1 Hitoshi Ando,1 Yumie Takeshita,1 Tsuguhito Ota,1 Masaru Sakurai,1
Tatsuya Yamashita,1 Eishiro Mizukoshi,1 Taro Yamashita,1 Masao Honda,1 Ken-ichi Miyamoto,2,3 Tetsuya Kubota,4
Naoto Kubota,4 Takashi Kadowaki,4 Han-Jong Kim,5 In-kyu Lee,5 Yasuhiko Minokoshi,6 Yoshiro Saito,7
Kazuhiko Takahashi,8 Yoshihiro Yamada,9 Nobuyuki Takakura,9 and Shuichi Kaneko1
1Department of Disease Control and Homeostasis
2Department of Hospital Pharmacy
3Department of Medicinal Informatics
Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa 920-8641, Japan
4Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan
5Section of Endocrinology, Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook
National University, Jungu, Daegu 700-412, Korea
6Division of Endocrinology and Metabolism, Department of Developmental Physiology, National Institute for Physiological Sciences,
Okazaki, Aichi 444-8585, Japan
7Department of Medical Life Systems, Faculty of Medical and Life Sciences, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan
8Department of Nutritional Biochemistry, Hokkaido Pharmaceutical University, Otaru, Hokkaido 047-0264, Japan
9Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan
10These authors contributed equally to this work
*Correspondence: ttakamura@m-kanazawa.jp
DOI 10.1016/j.cmet.2010.09.015SUMMARY
The liver may regulate glucose homeostasis by
modulating the sensitivity/resistance of peripheral
tissues to insulin, by way of the production of secre-
tory proteins, termed hepatokines. Here, we demon-
strate that selenoprotein P (SeP), a liver-derived
secretory protein, causes insulin resistance. Using
serial analysis of gene expression (SAGE) and DNA
chip methods, we found that hepatic SeP mRNA
levels correlated with insulin resistance in humans.
Administration of purified SeP impaired insulin
signaling and dysregulated glucose metabolism in
both hepatocytes and myocytes. Conversely, both
genetic deletion and RNA interference-mediated
knockdown of SeP improved systemic insulin sensi-
tivity and glucose tolerance in mice. The metabolic
actions of SeP were mediated, at least partly, by
inactivation of adenosine monophosphate-activated
protein kinase (AMPK). In summary, these results
demonstrate a role of SeP in the regulation of glucose
metabolism and insulin sensitivity and suggest that
SeP may be a therapeutic target for type 2 diabetes.
INTRODUCTION
Insulin resistance is an underlying feature of people with type 2
diabetes and metabolic syndrome (Saltiel and Kahn, 2001), but
is also associated with risk for cardiovascular diseases (Despre´s
et al., 1996) and contributes to the clinical manifestations ofCell Mnonalcoholic steatohepatitis (Ota et al., 2007). In an insulin-
resistant state, impaired insulin action promotes hepatic glucose
production and reduces glucose uptake by peripheral tissues,
resulting in hyperglycemia. The molecular mechanisms under-
lying insulin resistance are not fully understood, but are now
known to be influenced by the secretion of tissue-derived
factors, traditionally considered separate from the endocrine
system. Recent work in obesity research, for example, has
demonstrated that adipose tissues secrete a variety of proteins,
known as adipocytokines (Friedman and Halaas, 1998; Maeda
et al., 1996; Scherer et al., 1995; Steppan et al., 2001; Yang
et al., 2005), which can either enhance or impair insulin
sensitivity, thereby contributing to the development of insulin
resistance.
SeP (in humans encoded by the SEPP1 gene) is a secretory
protein primarily produced by the liver (Burk and Hill, 2005; Carl-
son et al., 2004). It contains ten selenocysteine residues and
functions as a selenium supply protein (Saito and Takahashi,
2002). However, the role of SeP in the regulation of glucose
metabolism and insulin sensitivity has not yet been established.
Furthermore, the clinical significance of SeP in human diseases
has not been well defined, although studies of SeP knockout
mice showed SeP deficiency to be associated with neurological
injury and low fertility (Hill et al., 2003; Schomburg et al., 2003).
The liver plays a central role in glucose homeostasis and is also
the site for the production of various secretory proteins. For
example, recent work in our laboratory has revealed that genes
encoding secretory proteins are abundantly expressed in the
livers of peoplewith type 2 diabetes (Misu et al., 2007).Moreover,
genes encoding angiogenic factors, fibrogenic factors, and
redox-associated factors were differentially expressed in the
livers of peoplewith type 2diabetes (Takamura et al., 2004; Take-
shita et al., 2006), possibly contributing to the pathophysiology ofetabolism 12, 483–495, November 3, 2010 ª2010 Elsevier Inc. 483
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Hepatokine Selenoprotein P and Insulin Resistancetype 2 diabetes and its clinical manifestations. On the basis of
these findings, we hypothesize that, analogous to adipose
tissues, the liver may also contribute to the development of
type 2 diabetes and insulin resistance, through the production
of secretory proteins, termed hepatokines.RESULTS
Identification of a Hepatic Secretory Protein Involved
in Insulin Resistance
To identify hepatic secretory proteins involved in insulin resis-
tance, we performed liver biopsies in humans and conducted a
comprehensive analysis of gene expression profiles, using two
distinct methods. First, we obtained human liver samples from
five patients with type 2 diabetes and five nondiabetic subjects
who underwent surgical procedures for malignant tumors, and
we subjected them to serial analysis of gene expression (SAGE)
(Velculescu et al., 1995). Consequently, we identified 117 genes
encoding putative secretory proteins with expression levels in
people with type 2 diabetes, 1.5-fold or greater higher than those
in normal subjects. Next, we obtained ultrasonography-guided
percutaneous needle liver biopsies from ten people with type 2
diabetes and seven normal subjects (Table S1 available online),
and we subjected them to DNA chip analysis to identify genes
whose hepatic expression was significantly correlated with
insulin resistance (Table S2). We performed glucose clamp
experiments on these human subjects and measured the meta-
bolic clearance rate (MCR) of glucose (glucose infusion rate
divided by the steady-state plasma glucose concentration) as
a measure of systemic insulin sensitivity. As a result, we found
that SEPP1 expression levels were upregulated 8-fold in people
with type 2 diabetes compared with normal subjects, as deter-
mined by SAGE (Table S2). Additionally, there was a negative
correlation between hepatic SEPP1 messenger RNA (mRNA)
levels and the MCR of glucose, indicating that elevated hepatic
SEPP1 mRNA levels were associated with insulin resistance
(Figure 1A). As a corollary, we found a positive correlation
between the levels of hepatic SEPP1 mRNA and postloaded or
fasting plasma glucose (Figures 1B and 1C).Elevation of SeP in Type 2 Diabetes
To characterize the role of SeP in the development of insulin
resistance, we measured serum SeP levels in human samples
(Table S3), using enzyme-linked immunosorbent assays (ELISA),
as described previously (Saito et al., 2001). Consistent with
elevated hepatic SEPP1 mRNA levels, we found a significant
positive correlation between serum SeP levels and both fasting
plasma glucose and hemoglobin A1c (HbA1c) levels (Figures 1D
and 1E). HbA1c is a clinical marker of protein glycation due to
hyperglycemia, and elevated HbA1c levels generally reflect
poor glucose control over a 2–3 month period. Additionally,
serum levels of SeP were significantly elevated in people with
type 2 diabetes compared with normal subjects (Figure 1F and
Table S4). Similar to data derived from clinical specimens, in
rodent models of type 2 diabetes, including OLETF rats and
KKAy mice, hepatic Sepp1 mRNA and serum SeP levels were
elevated (Figures 1G–1J and Table S5).484 Cell Metabolism 12, 483–495, November 3, 2010 ª2010 ElsevierSePExpression inHepatocytes Is Regulated byGlucose,
Palmitate, and Insulin
Toclarify the pathophysiology contributing to the hepatic expres-
sion of SeP in type 2 diabetes, we investigated the effects
of nutrient supply on Sepp1 mRNA expression in cultured
hepatocytes. We found that the addition of glucose or palmitate
upregulated Sepp1 expression, whereas insulin downregulated
it in a dose- and time-dependent manner (Figures 2A, 2C, 2E,
and 2F). Similar effects on SeP protein levels were observed
in primary mouse hepatocytes (Figures 2B, 2D, and 2G).
Consistent with the negative regulation of Sepp1 by insulin in
hepatocytes, Sepp1 mRNA levels were elevated in the livers of
fasting C57BL6J mice, compared with those that had been fed
(Figure 2H). Thus,multiple lines of evidence suggest that elevated
SeP is associated with the development of insulin resistance.
SeP Impairs Insulin Signaling and Dysregulates Glucose
Metabolism In Vitro
Because there is no existing cell culture or animal model in which
SeP is overexpressed, we purified SeP from human plasma
using chromatographic methods (Saito et al., 1999; Saito and
Takahashi, 2002) to examine the effects of SeP on insulin-
mediated signal transduction. Treatment of primary hepatocytes
with purified SeP induced a reduction in insulin-stimulated phos-
phorylation of insulin receptor (IR), and Akt (Figures 3A and 3B).
SeP exerts its actions through an increase in cellular glutathione
peroxidase (Saito and Takahashi, 2002). Coadministration of
BSO, a glutathione synthesis inhibitor, rescued cells from the
inhibitory effects of SeP (Figure 3C). Moreover, SeP increased
phosphorylation of IRS1 at Ser307, the downregulator of tyrosine
phosphorylation of IRS (Figure S1A). Similar effects of SeP were
also observed in C2C12 myocytes (Figure S1B). Next, we as-
sessed whether SeP dysregulated cellular glucose metabolism.
In H4IIHEC hepatocytes, treatment with SeP upregulated
mRNA expression of Pck1 and G6pc, key gluconeogenic
enzymes, resulting in a 30% increase in glucose release in the
presence of insulin (Figures 3D–3F). Treatment with SeP alone
had no effects on the levels of mRNAs encoding gluconeogenic
enzymes or on glucose production in the absence of insulin,
suggesting that SeP modulates insulin signaling. Additionally,
treatment with SeP induced a reduction in insulin-stimulated
glucose uptake in C2C12 myocytes (Figure 3G). These in vitro
experiments indicate that, at physiological concentrations, SeP
impairs insulin signal transduction and dysregulated cellular
glucose metabolism.
SeP Impairs Insulin Signaling and Disrupts Glucose
Homeostasis In Vivo
To examine the physiological effects of SeP in vivo, we treated
female C57BL/6J mice with two intraperitoneal injections of
purified human SeP (1 mg/kg body weight), 12 and 2 hr before
the experiments. Injection of purified human SeP protein
resulted in serum levels of 0.5–1.5 mg/mL (data not shown).
These levels correspond to the incremental change of SeP
serum levels in people with normal glucose tolerance to those
with type 2 diabetes (Saito et al., 2001). Glucose and insulin toler-
ance tests revealed that treatment of mice with purified SeP
induced glucose intolerance and insulin resistance (Figures 3H
and 3I). Blood insulin levels were significantly elevated inInc.
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Figure 1. Elevation of Serum SeP Levels
and Hepatic Sepp1 Expression in Type 2
Diabetes
(A–C) Individual correlations between hepatic
SEPP1 mRNA levels and metabolic clearance
rate (MCR) of glucose (A), postloaded plasma
glucose levels (B), and fasting plasma glucose
levels (C) in humans (n = 12–17). MCR equals the
glucose infusion rate divided by the steady-state
plasma glucose concentration, and is a measure
of systemic insulin sensitivity. MCR values were
determined by glucose clamp. SEPP1 mRNA
levels were quantified with DNA chips.
(D and E) Correlations between serum levels of
SeP and fasting plasma glucose levels (D) and
HbA1c (E) in people with type 2 diabetes (n = 35).
(F) Serum levels of SeP in people with type 2 dia-
betes and healthy subjects (n = 9–12). Age and
body weight were not significantly different
between the two groups. Data represents the
means ± SEM from two groups. *p < 0.05.
(G and H) Hepatic Sepp1mRNA levels in an animal
model of type 2 diabetes (n = 5–6).
(I and J) Serum SeP levels in an animal model of
type 2 diabetes. SeP was detected by western
blotting. Coomassie brilliant blue (CBB)-stained
gel is used as a control for protein loading. Graphs
display the results of densitometric quantification,
normalized to CBB-stained proteins (n = 5).
Data represent the mean ± SEM from five to six
mice per group. *p < 0.05, **p < 0.01. See also
Tables S1–S5.
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Hepatokine Selenoprotein P and Insulin ResistanceSeP-injected mice, although those of glucagon and GLP-1 were
unaffected during a glucose tolerance test (Figure S1C). Western
blot analysis showed a reduction in insulin-induced serine
phosphorylation of Akt in both liver and skeletal muscle of
SeP-injected mice (Figures 3J and 3K). Hyperinsulinemic-eugly-
cemic clamp studies showed that treatment with SeP
significantly increased endogenous glucose production and de-
creased peripheral glucose disposal (Figure S1D and Figures 3L
and 3M). Additionally, serum levels of injected human SeP
protein negatively correlated with rates of peripheral glucose
disposal (Figure S1E). These data indicate that SeP impairs
insulin signaling in the liver and skeletal muscle and induces
glucose intolerance in vivo.Cell Metabolism 12, 483–495,Knockdown of Sepp1 in Liver
Improves Glucose Intolerance
and Insulin Resistance in Mice
with Type 2 Diabetes
To determine whether knockdown of
endogenous Sepp1 enhances insulin
signaling, we transfected H4IIEC hepato-
cytes with Sepp1-specific small inter-
fering RNA (siRNA), and we observed a
reduction in endogenous Sepp1 mRNA
and SeP protein levels (Figures 4A and
4B). Insulin-stimulated serine phosphory-
lation of Akt was enhanced in these
treatedcells (Figure 4C). Similarly, delivery
of Sepp1-specific siRNAs into KKAy mice
via a hydrodynamic transfection method (McCaffrey et al., 2002;
Zender et al., 2003) resulted in a 30% reduction in SeP protein
levels in the liver and blood (Figures 4D–4G and Figure S2).
KnockdownofSepp1 improvedbothglucose intolerance (Figures
4Hand4I) and insulin resistance (Figures4Jand4K) inKKAymice.
SeP-Deficient Mice Show Improved Glucose Tolerance
and Enhanced Insulin Signaling in Liver and Muscle
We further confirmed the long-term effects of lowered SeP using
Sepp1 knockout mice (Hill et al., 2003). SeP knockout mice were
viable and displayed normal body weights when maintained on
a selenium-sufficient diet. Body weight, food intake, and O2
consumption were unaffected by SeP knockout (Figures S3ANovember 3, 2010 ª2010 Elsevier Inc. 485
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Figure 2. SeP Expression Is Regulated by Glucose, Palmitate, and Insulin
(A) Sepp1 mRNA levels in H4IIEC hepatocytes treated with glucose or mannitol (30 mM) for 6 hr (n = 4).
(B) SeP protein levels in primary hepatocytes treated with glucose or mannitol for 6 hr.
(C) Sepp1 mRNA levels in H4IIEC hepatocytes treated with palmitate (0.25 mM) for 16 hr (n = 5).
(D) SeP protein levels in primary hepatocytes treated with palmitate (0.25 mM) for 16 hr.
(E) Sepp1 and Pck1 mRNA levels in H4IIEC hepatocytes treated with various concentrations of insulin for 6 hr (n = 4).
(F) Sepp1 mRNA levels in H4IIEC hepatocytes treated with insulin (0.1 mg/ml) for the indicated periods of time (n = 4).
(G) SeP protein levels in primary hepatocytes treated with various concentrations of insulin for 6 hr.
(H) Liver Sepp1, Pck1, and G6pc mRNA levels in C57BL/6J mice following fasting for 12 hr and subsequent refeeding (n = 4).
Data in (A), (C), (E), and (F) represent the means ± SEM from four to five cells per group, and data in (H) represent the means ± SEM from four mice per group.
*p < 0.05, **p < 0.01.
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Hepatokine Selenoprotein P and Insulin Resistanceand S3B). Lipid accumulation in the liver and adipose tissues
was also unaffected (Figure 5A). However, postprandial plasma
levels of insulin were reduced in Sepp1/ mice, although blood
glucose levels remained unchanged (Figures 5B and 5C).
Glucose loading test revealed that Sepp1/ mice showed
improved glucose tolerance (Figure 5D). Insulin loading test
revealed that Sepp1/mice showed lower blood glucose levels
60 min after insulin injection (Figure 5E). Insulin signaling,
including phosphorylation of Akt and insulin receptor, was
enhanced in the liver and skeletal muscle of Sepp1/ mice
(Figures 5F–5K). Additionally, Sepp1+/ tended to show486 Cell Metabolism 12, 483–495, November 3, 2010 ª2010 Elsevierenhanced insulin sensitivity. Plasma levels of glucagon, active
GLP-1, and total GIP were unaffected by the loss of SeP in
both fasted and fed mice (Figure S3C), suggesting that SeP
dysregulated glucosemetabolism in vivo primarily bymodulating
the insulin pathway, but not by affecting other hormones,
including glucagon, GLP-1, and GIP.
SeP Deficiency Attenuates Adipocyte Hypertrophy
and Insulin Resistance in Dietary Obese Mice
To determine whether SeP deficiency reduces insulin resistance
caused by diet-induced obesity, we fed SeP knockout miceInc.
Cell Metabolism
Hepatokine Selenoprotein P and Insulin Resistancea high-fat, high-sucrose diet (HFHSD) that is known to induce
obesity, insulin resistance, and steatosis (Maeda et al., 2002).
HFHSD tended to induce body weight gains in wild-type and
Sepp1-deficient mice, although there was no significance
between the three groups of animals (Figure 6A). Daily food
intake was significantly increased in Sepp1/ mice compared
with wild-type animals (Figure 6B). Basal energy expenditure,
as measured by O2 consumption through indirect calorimetry,
was also increased in Sepp1/ mice (Figure 6C). Liver triglyc-
eride content and epididymal fat mass were unaffected by
Sepp1 gene deletion (Figures S4A and 6D). However, diet-
induced hypertrophy of adipocytes was attenuated in Sepp1/
mice (Figures 6E and 6F and Figure S4B). Additionally, serum
levels of free fatty acid and insulin were significantly reduced in
these animals (Figures 6G–6I). Glucose and insulin loading tests
revealed that Sepp1/ mice were protected against glucose
intolerance and insulin resistance even when on an obesity-
inducing diet (Figures 6J and 6K).
SeP Reduces Phosphorylation of AMPKa Both In Vitro
and In Vivo
Adenosinemonophosphate-activated protein kinase (AMPK) is a
serine/threonine kinase that phosphorylates a variety of energy-
associated enzymes and functions as a metabolic regulator that
promotes insulin sensitivity (Kahn et al., 2005). In this study, we
found that SeP treatment reduced phosphorylation of AMPKa
and ACC in both H4IIEC hepatocytes and mouse liver (Fig-
ures S5A and 7A). Fatty acid b oxidation and b oxidation-related
gene expression were also suppressed by SeP (Figures S5B–
S5D). The levels of AMP and ATP were unchanged in hepato-
cytes treated with SeP (Figure S5E). In contrast, Sepp1-deficient
mice exhibited increased phosphorylation of AMPKa and ACC in
the liver (Figure 7B). To determinewhether AMPKpathwayswere
involved in the action of SeP, we infected H4IIEC hepatocytes
with an adenovirus encoding dominant-negative (DN) or consti-
tutively active (CA) AMPK. Transduction with DN-AMPK reduced
insulin-stimulated Akt phosphorylation such that it could not be
further decreased by SeP (Figures 7C–7E). In contrast, when
CA-AMPK was overexpressed, SeP was unable to impair
insulin-stimulated Akt phosphorylation (Figures 7F–7H). Addi-
tionally, coadministration of 5-aminoimidazole-4-carboxyamide
ribonucleoside (AICAR), a known activator of AMPK, rescued
cells from the inhibitory effects of SeP on insulin signaling
(Figure 7I). These results suggest that reduced phosphorylation
of AMPK mediates, at least in part, the inhibitory effects of SeP
on insulin signal transduction. Next, we examined the effects
of SeP on some of the proteins that regulate the phosphorylation
of AMPK. SeP dose-dependently increased the levels of protein
phosphatase 2C (PP2C), a negative regulator of AMPK phos-
phorylation, in H4IIEC hepatocytes (Figure 7J). Expression of
LKB1 and CaMKKb, two positive regulators of AMPK, was
unaffected by SeP treatment.
DISCUSSION
A Liver-Derived Secretory Protein, SeP, Causes
Insulin Resistance
Our research reveals that hepatic overproduction of SeP contrib-
utes to the development of insulin resistance in the liver andCell Mskeletal muscle (Figure S5F). The liver plays a central role in
glucose homeostasis, mainly via glycogen storage and glucose
release into the blood stream. In addition, the liver is a major
site for the production of secretory proteins. Therefore, we
hypothesized that the liver would maintain glucose homeostasis
by producing liver-derived secretory protein(s) termed hepato-
kines. In fact, several studies have shown that hepatic secretory
factors, including the angiopoietin-like protein family (Oike et al.,
2005; Xu et al., 2005) and fetuin-A (Auberger et al., 1989; Srinivas
et al., 1993), are involved in insulin sensitivity. However, we spec-
ulated that the identification of the liver-derived proteins that
directly contribute to the pathogenesis of insulin resistance or
type 2 diabetes may not be adequate. Specifically, our compre-
hensive approach using global gene expression analyses re-
vealed that numerous genes encoding secretory proteins are
expressed and altered in the human type2 diabetic liver (Misu
et al., 2007). Thus, by comparing the expression levels and
clinical parameters for glycemic control and insulin resistance,
we selected candidate genes for liver-produced secretory
proteins that cause insulin resistance. The current study sheds
light on a previously underexplored function of the liver that is
similar to adipose tissue; the liver may participate in the patho-
genesis of insulin resistance through hormone secretion.
Suppression of SeP Expression by Insulin
in Hepatocytes
Our results indicate that insulin negatively regulates SeP
expression in hepatocytes. These findings are consistent
with recent reports that the SeP promoter is a target of FoxO
(forkhead box, class O) and PGC-1a (peroxisome proliferator-
activated receptor-g coactivator 1a), both of which are nega-
tively regulated by insulin in hepatocytes (Speckmann et al.,
2008; Walter et al., 2008). Consistent with these findings
in vitro, we showed that hepatic SeP expression was upregu-
lated in mice in the fasting state. Under hypoinsulinemic condi-
tions, such as a fasting state, upregulation of SeP might prevent
hypoglycemia by decreasing glucose uptake in peripheral
tissues and by increasing hepatic glucose production. Our
results raise the possibility that the liver regulates systemic
insulin sensitivity by sensing blood insulin levels and altering
the production of SeP.
SeP Decreases Phosphorylation of AMPK and ACC
in Hepatocytes
Identification of SeP receptor(s) in insulin-target organs is neces-
sary to clarify the action mechanisms of SeP. Several lines of
evidence have shown that apolipoprotein E receptor 2 (ApoER2)
functions as an SeP receptor in the testis (Olson et al., 2007) and
brain (Burk et al., 2007), both by acting as a cellular uptake
receptor and by inducing intracellular signaling (Masiulis et al.,
2009). It remains unknown whether ApoER2 acts as the SeP
receptor in the liver or skeletal muscle. However, in this study,
technical difficulties in the identification of a SeP receptor(s)
led us to screen for well-established pathways associated with
metabolic derangement to clarify the specific mechanisms of
SeP action. As a result, our experiments reveal that SeP reduces
phosphorylation of AMPK and its target ACC in H4IIEC hepato-
cytes and the livers of C57BL6J mice, possibly in an AMP/ATP
ratio-independent manner. AMPK functions as a regulator ofetabolism 12, 483–495, November 3, 2010 ª2010 Elsevier Inc. 487
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Figure 3. SeP Impairs Insulin Signaling In Vitro and In Vivo
(A and B) Effects of SeP on serine phosphorylation of Akt (A) and tyrosine phosphorylation of insulin receptor (B) in insulin-stimulated primary hepatocytes. Data
represent the means ± SEM of three independent experiments. *p < 0.05, **p < 0.01 (versus vehicle-treated cells). Primary hepatocytes were treated with SeP or
vehicle for 24 hr, and then the cells were stimulated with 1 ng/ml insulin for 15 min.
(C) Effects of BSO on SeP-induced changes in insulin-stimulated Akt phosphorylation in primary hepatocytes.
(D and E) Effects of SeP on the expression of mRNAs encoding gluconeogenic enzymes in H4IIEC hepatocytes (n = 5).
(F) Release of glucose from H4IIEC hepatocytes treated with SeP for 24 hr (n = 6).
(G) Effects of SeP on glucose uptake in C2C12 myocytes (n = 6).
(H and I) Glucose (H) and insulin (I) tolerance tests in mice injected with SeP or vehicle (n = 5). Glucose (1.5 g/kg body weight) and insulin (0.5 unit/kg body weight)
were administered intraperitoneally.
(J and K) Effects of SeP on serine phosphorylation of Akt in liver (J) and skeletal muscle (K) in mice injected with purified human SeP or vehicle. Mice (n = 3 or 4)
were stimulated with insulin (administered intraperitoneally). At 20 min after insulin stimulation, mice were anesthetized, and liver and hind-limb muscle samples
removed for analysis.
(L) Time course of glucose infusion rate (GIR) during hyperinsulinemic-euglycemic clamp in mice injected with SeP or vehicle (n = 6).
(M) GIR, endogenous glucose production (EGP), and rate of glucose disposal (Rd) during hyperinsulinemic-euglycemic clamp (n = 6).
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Cell Metabolism
Hepatokine Selenoprotein P and Insulin Resistancecellular energy homeostasis (Kahn et al., 2005) and mediates
some effects of peripheral hormones such as leptin (Minokoshi
et al., 2002) and adiponectin (Yamauchi et al., 2002); however,
the mechanisms by which these adipokines alter AMPK phos-
phorylation are not fully understood. Our present findings
demonstrate that SeP increases the levels of PP2C in H4IIEC
hepatocytes. PP2C is a phosphatase that inactivates AMPK by
dephosphorylating a threonine residue (Thr172) that lies in its
a-catalytic subunit (Davies et al., 1995). Tumor necrosis factor
a (TNF-a), a representative inflammatory cytokine linked to
insulin resistance, is known to reduce AMPK phosphorylation
by upregulating PP2C (Steinberg et al., 2006). Similar to
TNF-a, SeP may reduce AMPK phosphorylation, at least partly,
by upregulating PP2C. Further characterization of SeP and
SeP-receptor-mediated interactions will provide insights into
the involvement of SeP in PP2C upregulation and AMPK
dephosphorylation.Mechanism Underlying SeP-Mediated Insulin
Resistance Varies between Liver and Skeletal Muscle
Given that plasma SeP is derived mainly from the liver (Carlson
et al., 2004), our results suggest that AMPK mediates, at least
in part, the autocrine/paracrine action of SeP. One limitation of
our study is that the mechanism by which SeP acts on skeletal
muscle remains unknown. Unlike in the liver, SeP-induced
inhibitory effects on AMPK were not observed in either the
skeletal muscle of C57BL6J mice or C2C12 myocytes (data
not shown). Additionally, we showed that SeP reduces tyrosine
phosphorylation of insulin receptors in primary hepatocytes. In
contrast, SeP acts on serine phosphorylation of IRS1, but not
tyrosine phosphorylation of insulin receptors, in C2C12 myo-
cytes (data not shown). These results suggest that SeP disrupts
the insulin signal cascade at different levels between hepato-
cytes and myocytes. SeP might induce insulin resistance in
skeletal muscle, possibly through AMPK-independent path-
ways. The mechanisms that connect SeP to insulin resistance
likely exhibit tissue specificity.
We showed that SeP heterozygousmice have no phenotype in
glucose- and insulin-loading tests, whereas a 30% decrease in
SeP levels caused by the injection of siRNA improves glucose
tolerance and insulin resistance in KKAy mice. In general,
multiple compensatory changes are observed in knockout
mice, because the target gene has been absent since concep-
tion. In contrast, compensation may be inadequate in adult
animals in which the target gene has been knocked down with
siRNA. In fact, real-time PCR analysis showed that expression
of the gene encoding IL-6, a representative inflammatory cyto-
kine linked to insulin resistance, shows compensatory upregula-
tion in the liver of Sepp1/+mice, but not in Sepp1 siRNA-treated
KKAy mice (data not shown). Induction of IL-6 might compen-
sate for the 50% reduction in SeP levels in Sepp1/+ mice.
Actions of SeP on the central nervous system may contribute
to the in vivo phenotype. We did find that SeP-deficient mice fedC57BL/6Jmice were twice injected intraperitoneally with purified human SeP (1m
before the each experiment. Data in (D)–(G) represent the means ± SEM from five t
to six mice per group. *p < 0.05, **p < 0.01 versus cells treated with vehicle in (D)
Figure S1.
Cell Ma high-fat, high-sucrose diet display increases in food intake and
O2 consumption (Figures 6B and 6C), suggesting that SeP acts
on the central nervous system. Additionally, an earlier report
described the colocalization of SeP and amyloid-b protein in
the brains of people with Alzheimer’s disease, suggesting the
potential involvement of SeP in this condition’s pathology (Bellin-
ger et al., 2008). More recently, Takeda et al. reported that
amyloid pathology in Alzheimer’s disease may adversely affect
diabetic phenotypes in mice (Takeda et al., 2010). Further
experiments are necessary to determine whether the actions of
SeP on the central nervous system involve the in vivo phenotype
seen in this study.
We cannot exclude the possibility that the current phenotype
in Sepp1-deficient mice is affected by the abnormal distribution
of selenium. In fact, selenium levels in plasma and several tissues
have been reported to be reduced in Sepp1-deficient mice fed
a selenium-restricted diet (Schomburg et al., 2003). However,
Burk et al. reported that the selenium levels in all tissues except
the testis were unchanged in these mice fed a diet containing
adequate amounts of selenium (Hill et al., 2003). In this study,
we performed experiments using Sepp1-deficient mice fed
a diet containing adequate amounts of selenium. Thus, we
speculate that the effects of abnormal selenium distribution on
our results in Sepp1-deficient mice may be insignificant.
A limitation of this study is that we could not match age,
gender, or body weight completely between people with type 2
diabetes and normal subjects when comparing the serum SeP
levels, as a result of the limited sample numbers. However,
a previous large-scale clinical report showed that the age-,
gender-, race-, and BMI-adjusted mean serum selenium levels
were significantly elevated in participants with diabetes
compared with those without diabetes in the US population
(Bleys et al., 2007). Additionally, several lines of evidence
showed that serum selenium levels are positively correlated
with those of SeP in humans (Andoh et al., 2005; Persson-
Moschos et al., 1998). In combination with our result, these
reports lead us to speculate that serum SeP levels are also
elevated in people with type 2 diabetes compared with normal
subjects. However, additional large-scale clinical trials are
needed to address this.
In summary, our experiments have identified SeP as a liver-
derived secretory protein that induces insulin resistance and
hyperglycemia. Our findings suggest that the secretory protein
SeP may be a target for the development of therapies to
treat insulin resistance-associated diseases, including type 2
diabetes.EXPERIMENTAL PROCEDURES
Animals
Eight-week-old c57BL/6J mice were obtained from Sankyo Lab Service
(Tokyo, Japan). Male Otsuka Long-Evans Tokushima Fatty (OLETF) rats and
Long-Evans Tokushima Otsuka (LETO) rats were obtained from the Otsuka
Pharmaceutical Tokushima Research Institute (Tokushima, Japan). OLETFg/kg body weight) or vehicle in (H)–(M). Injectionswere administered 12 and 2 hr
o six cells per group, and data in (H)–(M) represent the means ± SEM from three
–(G). *p < 0.05, **p < 0.01 versus mice treated with vehicle in (H)–(M). See also
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Figure 4. Sepp1 Knockdown in the Liver Improves Insulin Sensitivity
(A) Sepp1 mRNA levels in H4IIEC hepatocytes transfected with control or Sepp1-specific siRNA (n = 4).
(B) SeP protein production in H4IIEC hepatocytes transfected with Sepp1-specific siRNA. SeP production was detected in whole cell lysates by western blotting.
(C) Effects of SeP knockdown on insulin-stimulated serine phosphorylation of Akt in H4IIEC hepatocytes. Data represent the mean ± SEM of three independent
experiments.
(D and E) Liver SeP production in KKAy mice injected with control or Sepp1-specific siRNA (n = 6). SeP protein levels were measured by western blotting 4 days
after injection of siRNA.
(F and G) Blood SeP levels in KKAy mice injected with siRNA. Blood samples were obtained 4 days after siRNA injection (n = 6).
(H–K) Intraperitoneal glucose (H and I) and insulin (J and K) tolerance tests in KKAy mice (n = 6–8) injected with control or Sepp1-specific siRNA. Glucose and
insulin was administered at doses of 0.3 g/kg body weight and 4 units/kg body weight, respectively.
Area under the curve (AUC) for blood glucose levels is shown in (I) and (K). Data in (A) represent the means ± SEM from four cells per group, and data in (E) and
(G)–(K) represent themeans ± SEM from six to eight mice per group. *p < 0.05 versus cells transfectedwith control siRNA in (A) and (C). *p < 0.05, **p < 0.01 versus
mice injected with control siRNA in (E) and (G)–(K). See also Figure S2.
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Hepatokine Selenoprotein P and Insulin Resistancerats have been established as an animal model of obesity-related type 2
diabetes (Kawano et al., 1992). Female KKAy mice were obtained from
CLEA Japan (Tokyo, Japan). All animals were housed in a 12 hr light/dark cycle
and allowed free access to food and water. High-fat and high-sucrose diet
(D03062301) was purchased from Research Diets (New Brunswick, NJ). The
experiments with OLETF and LETO rats were performed with frozen blood
and liver samples obtained in our previous study (Ota et al., 2007).490 Cell Metabolism 12, 483–495, November 3, 2010 ª2010 ElsevierPurification of SeP
SeP was purified from human plasma via conventional chromatographic
methods, as previously described (Saito et al., 1999; Saito and Takahashi,
2002). Homogeneity of purified human SeP was confirmed by analysis of
both amino acid composition and sequence (Saito et al., 1999). Concentra-
tions of purified SeP were measured by the Bradford method, using bovine
immunoglobulin G as a standard.Inc.
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Figure 5. Sepp1-Deficient Mice Show Improved Glucose Tolerance and Enhanced Insulin Sensitivity
(A) Hematoxylin-and-eosin-stained liver and epididymal fat sections from male Sepp1+/ and Sepp1/ mice.
(B) Blood glucose levels in Sepp1-deficient mice (n = 7). The mice were fasted for 6 hr.
(C) Blood insulin levels in Sepp1-deficient mice (n = 7).
(D and E) Intraperitoneal glucose (D) and insulin (E) tolerance tests in male Sepp1-deficient mice (n = 7). Glucose and insulin were administered at doses of
1.5 g/kg body weight and 4 units/kg body weight, respectively.
(F–K) Western blot analysis of phosphorylated Akt (pAkt) and phosphorylated insulin receptor (pIR) in liver (F–H) and skeletal muscle (I–K). Mice (n = 6) were
stimulated with insulin (administered intraperitoneally). At 20 min after insulin stimulation, mice were anesthetized, and liver and hind-limb muscle samples
removed for analysis.
Data in (B)–(E), (G), (H), (J), and (K) represent the means ± SEM from six to seven mice per group. *p < 0.05, **p < 0.01 versus wild-type mice. See also Figure S3.
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Delivery of siRNA targeted to the liver was performed by tail vein injections into
mice, via hydrodynamic techniques, as previously described (McCaffrey et al.,
2002; Zender et al., 2003). For these experiments, KKAy mice at 7–8 weeks ofCell Mage (31–33 g body weight) were used. Mice were anesthetized with pentobar-
bital, and 2 nmol of siRNA, diluted in 3 ml of PBS, was injected into the tail vein
over 15–20 s. All siRNAs were purchased from Applied Biosystems (SilencerR
In Vivo Ready Pre-designed siRNA). Sepp1 siRNAs with the followingetabolism 12, 483–495, November 3, 2010 ª2010 Elsevier Inc. 491
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Figure 6. Sepp1-Deficient Mice Are Protected from Diet-Induced Insulin Resistance and Adipocyte Hypertrophy
(A) Body weight of Sepp1-deficient and wild-type mice fed a high-fat, high-sucrose diet (HFHSD; n = 4–8). Sixteen-week-old male mice were fed a HFHSD for
16 weeks.
(B) Daily calorie intake in Sepp1-deficient and wild-type mice (n = 4–8).
(C) Energy expenditure (as measured by VO2 consumption through indirect calorimetry; n = 4).
(D) Epididymal fat mass in Sepp1-deficient and wild-type mice fed HFHSD (n = 4–7).
(E) Hematoxylin-and-eosin-stained epididymal fat sections from wild-type and Sepp1/ mice.
(F) Histogram showing adipocyte diameters.We determined adipocyte diameters bymeasuring at least 300 adipocytes randomly selected from four independent
sections.
(G) Blood nonestimated fatty acid levels in Sepp1-deficient and wild-type mice fed HFHSD (n = 4–7).
(H) Blood glucose levels in Sepp1-deficient and wild-type mice fed HFHSD (n = 4–8).
(I) Blood insulin levels inSepp1-deficient andwild-typemice fed HFHSD (n = 4–8). Blood samples were obtained frommice fed a HFHSD for 16weeks after a 12 hr
fast in (G)–(I).
(J) Intraperitoneal glucose tolerance tests in wild-type and Sepp1-deficient mice (n = 4–8). Glucose was administered at a dose of 0.3 g/kg body weight.
(K) Intraperitoneal insulin tolerance tests in wild-type and Sepp1-deficient mice (n = 5–10). Insulin was administered at a dose of 2.0 units/kg body weight.
Data in (A)–(D) and (G)–(K) represent the means ± SEM from four to ten mice per group. *p < 0.05, **p < 0.01 versus wild-type mice. See also Figure S4.
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Hepatokine Selenoprotein P and Insulin Resistancesequence were synthesized: mouse Sepp1, 50-GGUGUCAGAACACAUC
GCAtt-30 (sense). Negative control siRNAwas also used and had no significant
homology with any known gene sequences in mouse, rat, or human. Glucose
and insulin loading tests were performed 2–7 days after injection of mice with
siRNA.492 Cell Metabolism 12, 483–495, November 3, 2010 ª2010 ElsevierSeP Knockout Mice
SeP knockout mice were produced by homologous recombination with
genomic DNA cloned from an Sv-129 P1 library, as described previously
(Hill et al., 2003). As female SeP knockout mice had inconsistent phenotypes,
only male mice were used in this study.Inc.
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Figure 7. SeP Reduces Phosphorylation of AMPK and
ACC in Hepatocytes
(A) Phosphorylation of AMPK and ACC in the liver of mice
injected with SeP or vehicle. C57BL/6J mice were injected
intravenously with purified human SeP (1 mg/kg body weight)
or vehicle (phosphate-buffered saline). At 6 hr after injection,
the liver was removed.
(B) Phosphorylation of AMPK and ACC in the liver of Sepp1-
deficient mice after a 12 hr fast.
(C–E) Effects of dominant-negative AMPK on ACC phosphor-
ylation (C) and insulin-stimulated Akt phosphorylation (D and
E) in H4IIEC hepatocytes treated with SeP.
(F–H) Effects of constitutively active AMPK on ACC phosphor-
ylation (F) and insulin-stimulated Akt phosphorylation (G and
H) in H4IIEC hepatocytes treated with SeP.
(I) Effect of AICAR on SeP-induced insulin resistance in H4IIEC
hepatocytes.
(J) Levels of PP2C, CaMKKb, and LKB1 in H4IIEC hepatocytes
treated with various concentrations of SeP for 12 hr.
Data in (E) and (H) represent the means ± SEM from three
independent experiments. **p < 0.01 versus vehicle-treated
cells. See also Figure S5.
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All data were analyzed using the Japanese Windows Edition of the Statistical
Package for Social Science (SPSS) Version 11.0. Numeric values are reported
as the mean ± SEM. Differences between two groups were assessed with
unpaired two-tailed t tests. Data involving more than two groups were as-
sessed by analysis of variance (ANOVA). Glucose and insulin tolerance tests
were examined with repeated-measures ANOVA.
ACCESSION NUMBERS
Microarray data have been deposited in Gene Expression Omnibus under
accession number GSE23343.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at
doi:10.1016/j.cmet.2010.09.015.Cell MACKNOWLEDGMENTS
We thank Kuniaki Arai of Kanazawa University for liver biopsies and Isao Usui,
Hajime Ishihara, and Toshiyasu Sasaoka of Toyama University for supplying
their technical expertise on Western blot analyses of phosphoproteins. We
thank Yuriko Furuta and Yoko Hashimoto for technical assistance. We thank
Fabienne Foufelle of Universite´ Pierre et Marie Curie for providing adenovirus
vector encoding DN-AMPK. We are indebted to Kristina E. Hill and Raymond
F. Burk of Vanderbilt University School of Medicine for the Sepp1 knockout
mice. This work was supported by Takeda Science Foundation and
Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and
Technology, Japan. We also thank Cathie Chung for editing the manuscript.
Received: February 2, 2009
Revised: April 29, 2010
Accepted: August 13, 2010
Published: November 2, 2010etabolism 12, 483–495, November 3, 2010 ª2010 Elsevier Inc. 493
Cell Metabolism
Hepatokine Selenoprotein P and Insulin ResistanceREFERENCES
Andoh, A., Hirashima, M., Maeda, H., Hata, K., Inatomi, O., Tsujikawa, T.,
Sasaki, M., Takahashi, K., and Fujiyama, Y. (2005). Serum selenoprotein-P
levels in patients with inflammatory bowel disease. Nutrition 21, 574–579.
Auberger, P., Falquerho, L., Contreres, J.O., Pages, G., Le Cam, G., Rossi, B.,
and Le Cam, A. (1989). Characterization of a natural inhibitor of the insulin
receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic
activity. Cell 58, 631–640.
Bellinger, F.P., He, Q.P., Bellinger, M.T., Lin, Y., Raman, A.V., White, L.R., and
Berry, M.J. (2008). Association of selenoprotein p with Alzheimer’s pathology
in human cortex. J. Alzheimers Dis. 15, 465–472.
Bleys, J., Navas-Acien, A., and Guallar, E. (2007). Serum selenium and
diabetes in U.S. adults. Diabetes Care 30, 829–834.
Burk, R.F., and Hill, K.E. (2005). Selenoprotein P: an extracellular protein with
unique physical characteristics and a role in selenium homeostasis. Annu. Rev.
Nutr. 25, 215–235.
Burk, R.F., Hill, K.E., Olson, G.E.,Weeber, E.J., Motley, A.K., Winfrey, V.P., and
Austin, L.M. (2007). Deletion of apolipoprotein E receptor-2 in mice lowers
brain selenium and causes severe neurological dysfunction and death when
a low-selenium diet is fed. J. Neurosci. 27, 6207–6211.
Carlson, B.A., Novoselov, S.V., Kumaraswamy, E., Lee, B.J., Anver, M.R.,
Gladyshev, V.N., and Hatfield, D.L. (2004). Specific excision of the selenocys-
teine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role
of selenoproteins in liver function. J. Biol. Chem. 279, 8011–8017.
Davies, S.P., Helps, N.R., Cohen, P.T., and Hardie, D.G. (1995). 50-AMP
inhibits dephosphorylation, as well as promoting phosphorylation, of the
AMP-activated protein kinase. Studies using bacterially expressed human
protein phosphatase-2C alpha and native bovine protein phosphatase-2AC.
FEBS Lett. 377, 421–425.
Despre´s, J.P., Lamarche, B., Maurie`ge, P., Cantin, B., Dagenais, G.R.,
Moorjani, S., and Lupien, P.J. (1996). Hyperinsulinemia as an independent
risk factor for ischemic heart disease. N. Engl. J. Med. 334, 952–957.
Friedman, J.M., and Halaas, J.L. (1998). Leptin and the regulation of body
weight in mammals. Nature 395, 763–770.
Hill, K.E., Zhou, J., McMahan, W.J., Motley, A.K., Atkins, J.F., Gesteland, R.F.,
and Burk, R.F. (2003). Deletion of selenoprotein P alters distribution of
selenium in the mouse. J. Biol. Chem. 278, 13640–13646.
Kahn, B.B., Alquier, T., Carling, D., and Hardie, D.G. (2005). AMP-activated
protein kinase: ancient energy gauge provides clues to modern understanding
of metabolism. Cell Metab. 1, 15–25.
Kawano, K., Hirashima, T., Mori, S., Saitoh, Y., Kurosumi, M., and Natori, T.
(1992). Spontaneous long-term hyperglycemic rat with diabetic complications.
Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41, 1422–1428.
Maeda, K., Okubo, K., Shimomura, I., Funahashi, T., Matsuzawa, Y., and
Matsubara, K. (1996). cDNA cloning and expression of a novel adipose
specific collagen-like factor, apM1 (AdiPoseMost abundantGene transcript 1).
Biochem. Biophys. Res. Commun. 221, 286–289.
Maeda, N., Shimomura, I., Kishida, K., Nishizawa, H., Matsuda, M.,
Nagaretani, H., Furuyama, N., Kondo, H., Takahashi, M., Arita, Y., et al.
(2002). Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.
Nat. Med. 8, 731–737.
Masiulis, I., Quill, T.A., Burk, R.F., and Herz, J. (2009). Differential functions of
the Apoer2 intracellular domain in selenium uptake and cell signaling. Biol.
Chem. 390, 67–73.
McCaffrey, A.P., Meuse, L., Pham, T.T., Conklin, D.S., Hannon, G.J., and Kay,
M.A. (2002). RNA interference in adult mice. Nature 418, 38–39.
Minokoshi, Y., Kim, Y.B., Peroni, O.D., Fryer, L.G., Mu¨ller, C., Carling, D., and
Kahn, B.B. (2002). Leptin stimulates fatty-acid oxidation by activating
AMP-activated protein kinase. Nature 415, 339–343.
Misu, H., Takamura, T., Matsuzawa, N., Shimizu, A., Ota, T., Sakurai, M., Ando,
H., Arai, K., Yamashita, T., Honda, M., et al. (2007). Genes involved in oxidative
phosphorylation are coordinately upregulated with fasting hyperglycaemia in
livers of patients with type 2 diabetes. Diabetologia 50, 268–277.494 Cell Metabolism 12, 483–495, November 3, 2010 ª2010 ElsevierOike, Y., Akao,M., Yasunaga, K., Yamauchi, T., Morisada, T., Ito, Y., Urano, T.,
Kimura, Y., Kubota, Y., Maekawa, H., et al. (2005). Angiopoietin-related growth
factor antagonizes obesity and insulin resistance. Nat. Med. 11, 400–408.
Olson, G.E., Winfrey, V.P., Nagdas, S.K., Hill, K.E., and Burk, R.F. (2007).
Apolipoprotein E receptor-2 (ApoER2) mediates selenium uptake from
selenoprotein P by the mouse testis. J. Biol. Chem. 282, 12290–12297.
Ota, T., Takamura, T., Kurita, S., Matsuzawa, N., Kita, Y., Uno, M., Akahori, H.,
Misu, H., Sakurai, M., Zen, Y., et al. (2007). Insulin resistance accelerates a
dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132,
282–293.
Persson-Moschos, M., Alfthan, G., and Akesson, B. (1998). Plasma selenopro-
tein P levels of healthy males in different selenium status after oral supplemen-
tation with different forms of selenium. Eur. J. Clin. Nutr. 52, 363–367.
Saito, Y., and Takahashi, K. (2002). Characterization of selenoprotein P as
a selenium supply protein. Eur. J. Biochem. 269, 5746–5751.
Saito, Y., Hayashi, T., Tanaka, A., Watanabe, Y., Suzuki, M., Saito, E., and
Takahashi, K. (1999). Selenoprotein P in human plasma as an extracellular
phospholipid hydroperoxide glutathione peroxidase. Isolation and enzymatic
characterization of human selenoprotein p. J. Biol. Chem. 274, 2866–2871.
Saito, Y., Watanabe, Y., Saito, E., Honjoh, T., and Takahashi, K. (2001).
Production and application of monoclonal antibodies to human selenoprotein
P. J. Health Sci. 47, 346–352.
Saltiel, A.R., and Kahn, C.R. (2001). Insulin signalling and the regulation of
glucose and lipid metabolism. Nature 414, 799–806.
Scherer, P.E., Williams, S., Fogliano, M., Baldini, G., and Lodish, H.F. (1995).
A novel serum protein similar to C1q, produced exclusively in adipocytes.
J. Biol. Chem. 270, 26746–26749.
Schomburg, L., Schweizer, U., Holtmann, B., Flohe´, L., Sendtner, M., and
Ko¨hrle, J. (2003). Gene disruption discloses role of selenoprotein P in selenium
delivery to target tissues. Biochem. J. 370, 397–402.
Speckmann, B., Walter, P.L., Alili, L., Reinehr, R., Sies, H., Klotz, L.O., and
Steinbrenner, H. (2008). Selenoprotein P expression is controlled through
interaction of the coactivator PGC-1alpha with FoxO1a and hepatocyte
nuclear factor 4alpha transcription factors. Hepatology 48, 1998–2006.
Srinivas, P.R., Wagner, A.S., Reddy, L.V., Deutsch, D.D., Leon, M.A., Goustin,
A.S., and Grunberger, G. (1993). Serum alpha 2-HS-glycoprotein is an inhibitor
of the human insulin receptor at the tyrosine kinase level. Mol. Endocrinol. 7,
1445–1455.
Steinberg, G.R., Michell, B.J., van Denderen, B.J., Watt, M.J., Carey, A.L.,
Fam, B.C., Andrikopoulos, S., Proietto, J., Go¨rgu¨n, C.Z., Carling, D., et al.
(2006). Tumor necrosis factor alpha-induced skeletal muscle insulin resistance
involves suppression of AMP-kinase signaling. Cell Metab. 4, 465–474.
Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright,
C.M., Patel, H.R., Ahima, R.S., and Lazar, M.A. (2001). The hormone resistin
links obesity to diabetes. Nature 409, 307–312.
Takamura, T., Sakurai, M., Ota, T., Ando, H., Honda, M., and Kaneko, S.
(2004). Genes for systemic vascular complications are differentially expressed
in the livers of type 2 diabetic patients. Diabetologia 47, 638–647.
Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi,
D., Kurinami, H., Shinohara, M., Rakugi, H., and Morishita, R. (2010).
Diabetes-accelerated memory dysfunction via cerebrovascular inflammation
and Abeta deposition in an Alzheimer mouse model with diabetes. Proc.
Natl. Acad. Sci. USA 107, 7036–7041.
Takeshita, Y., Takamura, T., Hamaguchi, E., Shimizu, A., Ota, T., Sakurai, M.,
and Kaneko, S. (2006). Tumor necrosis factor-alpha-induced production of
plasminogen activator inhibitor 1 and its regulation by pioglitazone and
cerivastatin in a nonmalignant human hepatocyte cell line. Metabolism 55,
1464–1472.
Velculescu, V.E., Zhang, L., Vogelstein, B., and Kinzler, K.W. (1995). Serial
analysis of gene expression. Science 270, 484–487.
Walter, P.L., Steinbrenner, H., Barthel, A., and Klotz, L.O. (2008). Stimulation of
selenoprotein P promoter activity in hepatoma cells by FoxO1a transcription
factor. Biochem. Biophys. Res. Commun. 365, 316–321.Inc.
Cell Metabolism
Hepatokine Selenoprotein P and Insulin ResistanceXu, A., Lam, M.C., Chan, K.W., Wang, Y., Zhang, J., Hoo, R.L., Xu, J.Y., Chen,
B., Chow, W.S., Tso, A.W., and Lam, K.S. (2005). Angiopoietin-like protein 4
decreases blood glucose and improves glucose tolerance but induces
hyperlipidemia and hepatic steatosis in mice. Proc. Natl. Acad. Sci. USA
102, 6086–6091.
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S.,
Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002). Adiponectin stimulates
glucose utilization and fatty-acid oxidation by activating AMP-activated
protein kinase. Nat. Med. 8, 1288–1295.Cell MYang, Q., Graham, T.E., Mody, N., Preitner, F., Peroni, O.D., Zabolotny, J.M.,
Kotani, K., Quadro, L., and Kahn, B.B. (2005). Serum retinol binding protein 4
contributes to insulin resistance in obesity and type 2 diabetes. Nature 436,
356–362.
Zender, L., Hutker, S., Liedtke, C., Tillmann, H.L., Zender, S., Mundt, B.,
Waltemathe, M., Gosling, T., Flemming, P., Malek, N.P., et al. (2003). Caspase
8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad.
Sci. USA 100, 7797–7802.etabolism 12, 483–495, November 3, 2010 ª2010 Elsevier Inc. 495
